Actinium Seeks to Disrupt As Radioligand Candidate Succeeds In Pivotal Pre-Transplant AML Trial
The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.
You may also be interested in...
The Newark, New Jersey-based privately held company Actinium Pharmaceuticals, which is developing drugs combining cell-targeting antibodies with alpha-emitting radioisotopes to treat cancer, has secured approval from its shareholders to raise up to $25 million and seek a public listing.
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.